Orris

Why does the diabetes occur does it due to any conditions which patients had before if yes what alla re they and why they are the reason for diabetes

Reading File
Finding Sources
Finding Sources
Searching the Web

causes of diabetes mellitus predisposing conditions risk factors type 1 type 2

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have rich, detailed textbook content to build a thorough answer. Let me compile everything.

Why Does Diabetes Occur? Causes, Mechanisms, and Pre-existing Conditions

Diabetes mellitus is not a single disease - it is a group of metabolic disorders that all result in chronically high blood glucose (hyperglycemia). The cause depends on which type of diabetes is involved. Below is a full breakdown.

What Actually Happens in Diabetes

The pancreas produces a hormone called insulin, which acts like a "key" that lets glucose enter cells for energy. In diabetes, this system fails in one of two ways:
  1. The pancreas stops making enough insulin (or stops making it altogether), OR
  2. The body's cells stop responding to insulin properly (insulin resistance)
Either way, glucose builds up in the blood instead of entering cells.

Type 1 Diabetes - The Immune System Attacks the Pancreas

Core mechanism: The body's own immune system (T cells and antibodies) mistakenly destroys the insulin-producing beta cells in the pancreas. This is called an autoimmune attack. By the time symptoms appear, 80-90% of beta cells are already gone.

Pre-existing conditions and triggers that lead to Type 1:

Condition / FactorWhy it causes diabetes
HLA genetic haplotypes (DR4-DQ8, DR3-DQ2)These gene variants are found in ~90% of children with Type 1. They make the immune system more likely to attack its own beta cells. The DR15-DQ6 haplotype is actually protective.
Family history of autoimmune diseaseGenes that predispose to Type 1 overlap with genes for other autoimmune diseases (e.g., Hashimoto's thyroiditis, celiac disease). About 40 additional genes beyond HLA contribute.
Viral infections (mumps, rubella, coxsackievirus, COVID-19)These viruses carry proteins that resemble beta-cell proteins. In genetically predisposed people, the immune response against the virus accidentally attacks the pancreas too - a process called molecular mimicry. The SARS-CoV-2 pandemic notably triggered new-onset Type 1 cases.
Other autoimmune conditions already presentIf someone already has another autoimmune disorder, their immune system is primed to attack self-tissue - making beta cell destruction more likely.
Idiopathic (unknown) causesA small minority of Type 1 patients have no autoimmune markers at all; beta cells are destroyed for unclear reasons.
  • Goldman-Cecil Medicine, block 37, lines 689-700
  • Guyton & Hall Textbook of Medical Physiology, block 9, lines 2953-2959

Type 2 Diabetes - Insulin Resistance + Beta Cell Exhaustion

Core mechanism: Two problems work together - cells throughout the body (especially muscle, fat, liver) stop responding to insulin (insulin resistance), AND the pancreas gradually burns out trying to compensate (beta cell failure). By diagnosis, up to 50% of beta cells may have already failed.

Pre-existing conditions and risk factors that cause Type 2:

Non-Modifiable (you cannot change these)

Condition / FactorWhy it causes diabetes
Age ≥ 45 yearsBeta cell function naturally declines with age; cells accumulate damage over time
Family history / geneticsLifetime risk is ~40% with one diabetic parent, ~70% with two. Dozens of gene variants affect insulin signaling, beta cell function, and fat storage
Race/ethnicity (Asian, African American, Hispanic, Native American, Pacific Islander)Genetic differences in insulin sensitivity and fat distribution increase susceptibility at lower BMI thresholds

Metabolic Pre-existing Conditions (the most important category)

ConditionWhy it becomes diabetes
Prediabetes / Impaired fasting glucose / Impaired glucose toleranceBlood sugar is already elevated but not yet diabetic range - this IS insulin resistance beginning. Without intervention, most cases progress to full Type 2 diabetes
Obesity (especially abdominal/visceral fat)Visceral fat releases fatty acids and inflammatory signals that block insulin receptors in muscle and liver. Most Type 2 patients are overweight or obese
Polycystic Ovarian Syndrome (PCOS)PCOS causes insulin resistance as a core feature, meaning the insulin system is already compromised years before diabetes develops
Non-alcoholic Fatty Liver Disease (NAFLD)A fatty liver becomes insulin resistant and dumps excess glucose into the blood even without eating; it's both a consequence AND a cause of insulin resistance
Hypertension (high blood pressure)Shares common pathways with insulin resistance - high blood pressure and diabetes co-develop through inflammation and endothelial dysfunction
Dyslipidemia: Low HDL-C (<35 mg/dL) and/or High Triglycerides (>250 mg/dL)Excess circulating fats directly impair insulin signaling in cells (lipotoxicity)
Gestational Diabetes (during pregnancy)Women who develop diabetes during pregnancy have shown their beta cells can be stressed by insulin resistance; they retain a 30-70% lifetime risk of developing Type 2 diabetes later
Personal history of cardiovascular diseaseAtherosclerosis, heart attack history, and diabetes share root causes: insulin resistance, inflammation, and metabolic dysfunction
Acanthosis nigricansThis skin condition (dark, velvety patches at skin folds) is a direct skin sign of insulin resistance - it appears because insulin is acting on skin receptors in excess
Obstructive Sleep Apnea / Sleep deprivationDisrupted sleep raises cortisol and ghrelin, directly increasing blood sugar and causing insulin resistance; night-shift workers have measurably higher diabetes rates
Goldman-Cecil Medicine, Table 210-5, lines 834-874

Lifestyle / Acquired Risk Factors

FactorMechanism
Physical inactivityMuscle is the largest glucose-consuming organ. Inactive muscle becomes insulin resistant
Unhealthy diet (high sugar, processed carbs, saturated fat)Overwhelms insulin capacity and promotes visceral fat accumulation
SmokingIncreases cortisol, causes oxidative stress in beta cells, and directly causes insulin resistance
Long-term glucocorticoid (steroid) therapySteroids (prednisone, dexamethasone) directly raise blood glucose by promoting gluconeogenesis in the liver and causing insulin resistance - this is called steroid-induced diabetes
Antipsychotic medications (e.g., clozapine, olanzapine)These drugs cause significant weight gain and metabolic changes that strongly promote insulin resistance

Type 3c Diabetes - Pancreatic Disease

A less recognized but important form: diabetes caused by physical damage to the pancreas itself (not autoimmune). Conditions that destroy the exocrine pancreas also destroy the neighboring beta cells:
  • Chronic pancreatitis (often from alcohol)
  • Pancreatic cancer
  • Cystic fibrosis
  • Hemochromatosis (iron overload damaging pancreas)
  • Surgical removal of the pancreas

Summary Diagram

PRE-EXISTING CONDITIONS
        |
        ├── AUTOIMMUNE GENES + VIRAL TRIGGER
        |           → Immune attack on beta cells
        |           → Absolute insulin deficiency
        |           → TYPE 1 DIABETES
        |
        ├── OBESITY + INACTIVITY + GENETICS
        |           → Insulin resistance in muscle/liver/fat
        |           → Beta cells work harder → eventually exhaust
        |           → TYPE 2 DIABETES
        |
        └── PANCREATIC DISEASE / MEDICATIONS
                    → Physical destruction of beta cells
                    → TYPE 3c / SECONDARY DIABETES

Key Takeaway

Yes - many conditions that patients have BEFORE getting diabetes directly cause it:
  • Prediabetes, PCOS, NAFLD, and gestational diabetes are the strongest precursors - they already represent degrees of insulin failure
  • Obesity and metabolic syndrome are the single biggest modifiable drivers of Type 2
  • Genetic HLA variants and viral infections are the triggers for Type 1
  • Steroid use, antipsychotics, and sleep disorders are underappreciated causes
The earlier these pre-existing conditions are identified and treated, the better the chance of preventing diabetes from developing.
attachment
attachment

Can you explain the above uploaded image and can you tell me how to explain ADA guidelines 2026

analyse_media
Searching the Web

ADA Standards of Care diabetes 2026 glucose lowering medications guidelines updates

Finding Sources
Reading Web Page

https://diabetesonthenet.com/diabetes-primary-care/factsheet…

Here is a full explanation of the image and the ADA 2026 guidelines context.

Image Explanation: ADA Flowchart - Glucose-Lowering Medications in Type 2 Diabetes

The image is the ADA's official algorithm for selecting glucose-lowering medications in Type 2 Diabetes. It is organized around two major goals and one additional pathway at the bottom.

The Foundation (Top of Chart - Always Apply First)

Healthy lifestyle behaviors + Diabetes Self-Management Education (DSMES) + Social Determinants of Health are the base of ALL diabetes care - regardless of which medication path is followed. The teal circle in the top right reminds clinicians: reassess and modify treatment every 3-6 months to avoid "therapeutic inertia" (not changing treatment when it should be changed).

LEFT SIDE: Goal - Cardiovascular and Kidney Risk Reduction (Red/Dark pathway)

This side applies when the patient has specific comorbidities that increase their risk of heart or kidney complications. It is divided into 4 branches:

Branch 1: + ASCVD (Atherosclerotic Cardiovascular Disease) or Indicators of High CVD Risk

  • First choice: GLP-1 RA with proven CVD benefit (e.g., semaglutide, liraglutide)
  • OR: SGLT2i with proven CVD benefit (e.g., empagliflozin, canagliflozin)
  • If glycemia is still above goal: consider adding an SGLT2i to a GLP-1 RA (or vice versa), or add Pioglitazone (with caution - risk of heart failure, bone loss, bladder cancer)

Branch 2: + Heart Failure (HF)

  • SGLT2 inhibitor with proven HF benefit - this is the primary drug for patients with HF
  • If the patient also has obesity + symptomatic HFrEF or HFpEF: add dual GLP-1 RA or GLP-1 RA with proven HF benefit
  • New in 2026: GIP/GLP-1 RAs (tirzepatide) are now included for HFpEF patients

Branch 3: + Chronic Kidney Disease (CKD)

  • Defined as: eGFR < 60 mL/min/1.73m² OR albumin-creatinine ratio (ACR) ≥ 3.0 mg/mmol
  • On maximally tolerated ACEi or ARB (kidney-protective blood pressure drugs):
    • SGLT2i with primary evidence for slowing CKD progression - can start when eGFR ≥ 20
    • Note: glucose-lowering benefit of SGLT2i is reduced when eGFR < 45
    • OR: GLP-1 RA with proven CKD benefit (new in 2026 - GLP-1 RAs can now be used in CKD including advanced CKD and even dialysis patients for CV protection)
    • If glycemia still above goal: add GLP-1 RA to SGLT2i or vice versa

Branch 4: + High CVD risk (combined ASCVD/indicators)

Loops back - same logic as Branch 1.

RIGHT SIDE: Goal - Weight and Glycemic Achievement (Orange pathway)

This side focuses on patients who need better blood sugar control or weight loss, without specific cardiac/kidney disease driving the drug choice.

Weight Management (Efficacy for Weight Loss - tiered list):

TierDrugs
Very HighSemaglutide, Tirzepatide
HighDulaglutide, Liraglutide
IntermediateGLP-1 RA (others), SGLT2i
NeutralMetformin, DPP-4i

Glycemic Control (Efficacy for Glucose Lowering - tiered list):

TierDrugs
Very HighHigh-dose dulaglutide, Semaglutide, Tirzepatide, Combination injectable (GLP-1 RA + insulin)
HighGLP-1 RA (others), Metformin, Pioglitazone, SGLT2i, Sulfonylurea
IntermediateDPP-4i
  • Key note: Prioritize avoidance of hypoglycemia in high-risk individuals (elderly, those with impaired awareness)
  • Metformin or another agent providing adequate efficacy remains a first-line glycemic option

If Glycemia is Still Above Goal or Barriers Exist:

  • Refer to DSMES (diabetes self-management education)
  • Consider CGM (continuous glucose monitor) - new in 2026: now RECOMMENDED (not just "considered") for all adults with Type 2 on insulin, on hypoglycemia-risk drugs, or when CGM aids management
  • Identify SDOH (social determinants of health) that block treatment goals - e.g., cost, food access, health literacy

BOTTOM PATHWAY: MASLD / MASH (Liver Disease)

Both pathways converge here when liver disease is also present:
  • MASLD = Metabolic dysfunction-associated steatotic liver disease (fatty liver)
  • MASH = Metabolic dysfunction-associated steatohepatitis (inflamed/scarring fatty liver)
Recommended agents: GLP-1 RA, dual GIP/GLP-1 RA (tirzepatide), Pioglitazone, or GLP-1 RA + pioglitazone combination - all have proven or potential benefit in reversing liver fat and inflammation.
Special note: Use insulin in decompensated cirrhosis (when the liver has failed - oral agents are unsafe).

Key Drug Class Abbreviations Decoded

AbbreviationFull NameExamples
GLP-1 RAGlucagon-like peptide-1 receptor agonistSemaglutide (Ozempic), Liraglutide (Victoza), Dulaglutide (Trulicity)
SGLT2iSodium-glucose cotransporter-2 inhibitorEmpagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin
DPP-4iDipeptidyl peptidase-4 inhibitorSitagliptin (Januvia), Saxagliptin
GIP/GLP-1 RA (dual)Dual incretin agonistTirzepatide (Mounjaro/Zepbound)
ACEi/ARBBlood pressure drugs protecting kidneysLisinopril, Losartan
nsMRANon-steroidal mineralocorticoid receptor antagonistFinerenone - NEW in 2026

ADA 2026 Key Updates (What Changed from Previous Years)

The 2026 Standards of Care (published January 2026) made several important updates that are reflected in this chart:

1. GLP-1 RAs Now Approved for CKD (including advanced CKD)

Previously, GLP-1 RAs were used cautiously in kidney disease. The 2026 guidelines now explicitly recommend GLP-1-based therapy even in advanced CKD and dialysis patients - purely for cardiovascular risk reduction.

2. Tirzepatide (dual GIP/GLP-1 RA) Added for Heart Failure

GIP/GLP-1 RAs are now formally listed alongside GLP-1 RAs for patients with HFpEF (heart failure with preserved ejection fraction) + obesity - recognizing tirzepatide's expanded evidence base.

3. Non-Steroidal MRA (Finerenone) Added

A brand-new drug class in the guidelines: nsMRA (specifically finerenone) is now recommended for patients with symptomatic Stage C heart failure with ejection fraction >40% AND diabetes.

4. CGM Now a STANDARD RECOMMENDATION (not optional)

CGM is now formally recommended - not just "considered" - for:
  • All adults on insulin (including older adults)
  • Adults on non-insulin therapies that risk hypoglycemia
  • Any diabetes treatment where CGM improves management

5. GLP-1 RAs in MASH

Certain GLP-1 RAs now have evidence-backed recommendations for biopsy-proven MASH or high fibrosis risk patients.

6. SGLT2i + nsMRA Can Be Co-Started in CKD

For patients with eGFR 30-90 and ACR ≥ 100 mg/g, simultaneous initiation of both SGLT2i and nsMRA is now an option alongside RAS blocker therapy.

How to Read This Chart Clinically (Step-by-Step)

  1. Start every patient on lifestyle + DSMES + address SDOH
  2. Ask: Does the patient have ASCVD, High CVD risk, HF, or CKD?
    • YES → Go LEFT side, pick the branch that matches their condition, use disease-specific drugs first
  3. Ask: Is glycemia or weight the main unmet need?
    • YES → Go RIGHT side, pick drug tier based on how much glucose/weight lowering is needed
  4. Reassess every 3-6 months - if not at goal, combine across pathways
  5. Check for MASLD/MASH - if present, ensure GLP-1 RA or pioglitazone is included
  6. Use insulin only when other agents fail or in decompensated liver disease
The key philosophy of this chart is: treat the underlying comorbidity first, treat glucose second - because choosing the right drug for the heart/kidney also lowers blood sugar, so you get both benefits with one drug.
This is a shared conversation. Sign in to Orris to start your own chat.